Getinge AB (publ) (GETI-B.ST)
SEK 194.15
(-0.89%)
SEK 194.15
(-0.89%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 5.4 Billion SEK | 3554.05% |
| 2022 | 148 Million SEK | -35.65% |
| 2021 | 230 Million SEK | -94.46% |
| 2020 | 4.15 Billion SEK | -52.66% |
| 2019 | 8.76 Billion SEK | -8.27% |
| 2018 | 9.55 Billion SEK | -1.6% |
| 2017 | 9.71 Billion SEK | -51.5% |
| 2016 | 20.02 Billion SEK | 1.04% |
| 2015 | 19.81 Billion SEK | 2.83% |
| 2014 | 19.26 Billion SEK | 20.27% |
| 2013 | 16.02 Billion SEK | -1.54% |
| 2012 | 16.27 Billion SEK | 5.1% |
| 2011 | 15.48 Billion SEK | 33.89% |
| 2010 | 11.56 Billion SEK | -21.14% |
| 2009 | 14.66 Billion SEK | 25.93% |
| 2008 | 11.64 Billion SEK | 39.97% |
| 2007 | 8.31 Billion SEK | 122.14% |
| 2006 | 3.74 Billion SEK | 9.33% |
| 2005 | 3.42 Billion SEK | 6.6% |
| 2004 | 3.21 Billion SEK | 17.24% |
| 2003 | 2.74 Billion SEK | 36.87% |
| 2002 | 2 Billion SEK | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 4.97 Billion SEK | -8.04% |
| 2024 Q3 | 6.89 Billion SEK | 36.4% |
| 2024 Q2 | 6.32 Billion SEK | 27.19% |
| 2023 Q3 | 1.47 Billion SEK | -39.93% |
| 2023 Q1 | 1.19 Billion SEK | 704.73% |
| 2023 Q2 | 2.45 Billion SEK | 106.47% |
| 2023 FY | 5.4 Billion SEK | 3554.05% |
| 2023 Q4 | 5.4 Billion SEK | 266.15% |
| 2022 Q2 | 1.24 Billion SEK | 4382.76% |
| 2022 Q3 | 660 Million SEK | -46.86% |
| 2022 FY | 148 Million SEK | -35.65% |
| 2022 Q4 | 148 Million SEK | -77.58% |
| 2022 Q1 | -29 Million SEK | -112.61% |
| 2021 Q1 | 2.39 Billion SEK | -42.41% |
| 2021 Q4 | 230 Million SEK | -74.47% |
| 2021 Q3 | 901 Million SEK | -55.83% |
| 2021 FY | 230 Million SEK | -94.46% |
| 2021 Q2 | 2.04 Billion SEK | -14.64% |
| 2020 Q2 | 7.43 Billion SEK | -18.54% |
| 2020 Q4 | 4.15 Billion SEK | -34.34% |
| 2020 FY | 4.15 Billion SEK | -52.66% |
| 2020 Q1 | 9.12 Billion SEK | 4.07% |
| 2020 Q3 | 6.32 Billion SEK | -14.96% |
| 2019 Q4 | 8.76 Billion SEK | -15.53% |
| 2019 FY | 8.76 Billion SEK | -8.27% |
| 2019 Q3 | 10.37 Billion SEK | -1.51% |
| 2019 Q2 | 10.53 Billion SEK | -1.5% |
| 2019 Q1 | 10.69 Billion SEK | 11.95% |
| 2018 Q2 | 10.62 Billion SEK | 7.21% |
| 2018 Q3 | 9.79 Billion SEK | -7.82% |
| 2018 FY | 9.55 Billion SEK | -1.6% |
| 2018 Q4 | 9.55 Billion SEK | -2.41% |
| 2018 Q1 | 9.9 Billion SEK | 2.04% |
| 2017 Q1 | 19.39 Billion SEK | -3.13% |
| 2017 Q4 | 9.71 Billion SEK | -33.61% |
| 2017 Q3 | 14.62 Billion SEK | -24.98% |
| 2017 Q2 | 19.49 Billion SEK | 0.53% |
| 2017 FY | 9.71 Billion SEK | -51.5% |
| 2016 Q4 | 20.02 Billion SEK | -0.48% |
| 2016 Q3 | 20.11 Billion SEK | -0.54% |
| 2016 Q1 | 19.67 Billion SEK | -0.71% |
| 2016 FY | 20.02 Billion SEK | 1.04% |
| 2016 Q2 | 20.22 Billion SEK | 2.81% |
| 2015 Q1 | 20.25 Billion SEK | 5.09% |
| 2015 FY | 19.81 Billion SEK | 2.83% |
| 2015 Q4 | 19.81 Billion SEK | -2.65% |
| 2015 Q3 | 20.35 Billion SEK | 0.76% |
| 2015 Q2 | 20.2 Billion SEK | -0.24% |
| 2014 Q2 | 18.03 Billion SEK | 19.8% |
| 2014 Q1 | 15.05 Billion SEK | -6.06% |
| 2014 FY | 19.26 Billion SEK | 20.27% |
| 2014 Q4 | 19.26 Billion SEK | 1.77% |
| 2014 Q3 | 18.93 Billion SEK | 5.01% |
| 2013 Q3 | 14.98 Billion SEK | -14.6% |
| 2013 Q2 | 17.55 Billion SEK | 1732.56% |
| 2013 Q1 | -1.07 Billion SEK | -106.61% |
| 2013 FY | 16.02 Billion SEK | -1.54% |
| 2013 Q4 | 16.02 Billion SEK | 6.89% |
| 2012 Q1 | -1.13 Billion SEK | -107.31% |
| 2012 Q2 | -1.21 Billion SEK | -7.78% |
| 2012 Q3 | -1.39 Billion SEK | -14.19% |
| 2012 FY | 16.27 Billion SEK | 5.1% |
| 2012 Q4 | 16.27 Billion SEK | 1268.89% |
| 2011 Q1 | -1.02 Billion SEK | -108.87% |
| 2011 Q4 | 15.48 Billion SEK | 1524.29% |
| 2011 FY | 15.48 Billion SEK | 33.89% |
| 2011 Q3 | -1.08 Billion SEK | -5.53% |
| 2011 Q2 | -1.03 Billion SEK | -0.39% |
| 2010 Q1 | -1.25 Billion SEK | -108.58% |
| 2010 FY | 11.56 Billion SEK | -21.14% |
| 2010 Q4 | 11.56 Billion SEK | 1055.62% |
| 2010 Q3 | -1.21 Billion SEK | 11.74% |
| 2010 Q2 | -1.37 Billion SEK | -8.98% |
| 2009 Q4 | 14.66 Billion SEK | 0.0% |
| 2009 FY | 14.66 Billion SEK | 25.93% |
| 2008 FY | 11.64 Billion SEK | 39.97% |
| 2007 FY | 8.31 Billion SEK | 122.14% |
| 2006 FY | 3.74 Billion SEK | 9.33% |
| 2005 FY | 3.42 Billion SEK | 6.6% |
| 2004 FY | 3.21 Billion SEK | 17.24% |
| 2003 FY | 2.74 Billion SEK | 36.87% |
| 2002 FY | 2 Billion SEK | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Acarix AB (publ) | -35.14 Million SEK | 15485.928% |
| ADDvise Group AB (publ) | 1.22 Billion SEK | -340.786% |
| ADDvise Group AB (publ) | 1.22 Billion SEK | -340.786% |
| Arcoma AB | -1.12 Million SEK | 479532.624% |
| Bactiguard Holding AB (publ) | 109.88 Million SEK | -4821.643% |
| BICO Group AB (publ) | 927.9 Million SEK | -482.821% |
| Boule Diagnostics AB (publ) | 128.8 Million SEK | -4098.758% |
| CellaVision AB (publ) | -56.94 Million SEK | 9597.383% |
| Clinical Laserthermia Systems AB (publ) | -14.87 Million SEK | 36451.415% |
| Chordate Medical Holding AB (publ) | -8.45 Million SEK | 64060.564% |
| C-Rad AB (publ) | -127.6 Million SEK | 4338.245% |
| Duearity AB (publ) | 10.23 Million SEK | -52758.958% |
| Dignitana AB (publ) | 13.07 Million SEK | -41255.051% |
| Episurf Medical AB (publ) | -52.7 Million SEK | 10361.86% |
| Scandinavian Real Heart AB (Publ) | -35.05 Million SEK | 15528.028% |
| Iconovo AB (publ) | -10.75 Million SEK | 50382.023% |
| Integrum AB (publ) | -10.47 Million SEK | 51720.116% |
| Luxbright AB (publ) | -13.83 Million SEK | 39193.601% |
| Mentice AB (publ) | -49.56 Million SEK | 11011.145% |
| OssDsign AB (publ) | -162.78 Million SEK | 3422.112% |
| Paxman AB (publ) | -11.41 Million SEK | 47492.867% |
| Promimic AB (publ) | -50.32 Million SEK | 10846.577% |
| Qlife Holding AB (publ) | 19.07 Million SEK | -28258.679% |
| SciBase Holding AB (publ) | -27.32 Million SEK | 19892.124% |
| ScandiDos AB (publ) | -1.53 Million SEK | 353333.181% |
| Sectra AB (publ) | -772.85 Million SEK | 799.746% |
| Sedana Medical AB (publ) | -226.87 Million SEK | 2483.702% |
| Senzime AB (publ) | -139.54 Million SEK | 3975.563% |
| SpectraCure AB (publ) | -50.23 Million SEK | 10865.617% |
| Stille AB | -178.5 Million SEK | 3129.624% |
| Vitrolife AB (publ) | 1.22 Billion SEK | -340.391% |
| Xvivo Perfusion AB (publ) | -214.65 Million SEK | 2619.439% |